[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-diseases-cvd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-diseases-cvd":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,54,84,111,132,158,188,210,238,261,293,329,360,380,415,446,482,507,537,570,599,624,647,676,707],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100645108","randomized-cross-over-comparison-of-medium-cut-off-and-high-flux-hemodialysis-membranes-100645108",false,"NCT07679763","Randomized Cross-Over Comparison of Medium Cut-Off and High-Flux Hemodialysis Membranes","Randomized Cross-Over Evaluation of Medium Cut-Off and High-Flux Hemodialysis Membranes on Inflammation and Cardiovascular Function in Maintenance Hemodialysis Patients","MCO-HD","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Receiving maintenance hemodialysis for at least 6 months.\n* Clinically stable and receiving thrice-weekly hemodialysis.\n* Able to comply with study procedures, questionnaires, and scheduled assessments.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute infection at screening or enrollment.\n* Major surgery within the previous 3 months.\n* Active malignancy requiring ongoing treatment.\n* Terminal illness with limited life expectancy.\n* Physical or cognitive impairment preventing completion of study procedures or questionnaires.\n* Inability or unwillingness to provide written informed consent.","ALL","18 Years","80 Years",{"count":5,"type":22},"ESTIMATED","INTERVENTIONAL",[25],"NA","Patients receiving maintenance hemodialysis are at increased risk of cardiovascular disease, chronic inflammation, endothelial dysfunction, and impaired quality of life. Medium cut-Off (MCO) hemodialysis membranes have been developed to enhance the removal of middle-molecular-weight uremic toxins compared with conventional high-flux membranes, which may improve inflammatory status and cardiovascular health.\n\nThe aim of this study is to compare the effects of MCO and high-flux hemodialysis membranes on inflammatory biomarkers and cardiovascular function in adult patients receiving maintenance hemodialysis. The primary outcomes are changes in serum interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) levels. Secondary outcomes include arterial stiffness assessed by pulse wave velocity (PWV), body composition assessed by Body Composition Monitor (BCM), handgrip strength, and patient-reported outcomes including quality of life, pruritus, and pain scores.\n\nThis is a prospective, randomized, open-label, two-sequence, two-period crossover study conducted at Gazi University Faculty of Medicine. Thirty adult hemodialysis patients will be randomized to one of two treatment sequences. Participants in Sequence A will receive MCO dialysis membranes for the first 3 months followed by high-flux membranes for the next 3 months. Participants in Sequence B will receive high-flux membranes for the first 3 months followed by MCO membranes for the next 3 months. Blood samples and clinical assessments will be performed at baseline, month 3, and month 6.\n\nThe study is expected to provide evidence regarding the effects of different dialysis membrane technologies on inflammation and cardiovascular health and may contribute to optimizing membrane selection in routine hemodialysis practice.",[28,29,30,31],"End Stage Kidney Disease (ESKD)","Hemodialysis","Cardiovascular Diseases (CVD)","Inflammation",[33,34,35,36,37,31,38,39,40],"End-Stage Kidney Disease","High-Flux Hemodialysis","Medium Cut-Off Membrane","Interleukin-6","VCAM-1","Cardiovascular Function","Pulse Wave Velocity","Body Composition Monitor","NOT_YET_RECRUITING","2026-06-30",{"date":44,"type":45},"2026-07-01","ACTUAL",{"date":47,"type":22},"2026-07",{"date":49,"type":22},"2027-01",{"name":51,"class":52},"Gazi University","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":53},"100630117","the-effects-of-a-6-week-pre-operative-administration-of-a-microbiome-modulator-wellbiome-versus-placebo-on-cardiac-surgical-outcomes-and-nhs-cost-savings-100630117","NCT07483502","The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator \"WellBiome\" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.","A Double Blind, Placebo Controlled 6- Week Pre-operative Randomised Clinical Trial of a Microbiome Modulator \"WellBiome\" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.","INCLUSION CRITERIA:\n\n* Aged 50-80\n* BMI ≥ 25-40kg\u002Fm²\n* Waist circumference \\>94cm (men) and 88cm (women)\n* HbA1c 42-58 mmol\u002Fmol (6.0-7.5 old HbA1c units)\n* No known intolerances to oligosaccharides and xylooligosaccharides\n* Be stable dose of cholesterol and blood pressure medication for 3 months\n* Be willing to participate and sign to that effect.\n\nEXCLUSION CRITERIA\n\n* Active cancer\n* Any gastro-intestinal surgery or currently under the care of the GI clinical team for any clinically significant digestive issue (Crohn's, IBS, ulcerative colitis).\n* On or had antibiotic treatment in the last 3 months.\n* Patients who have taken ibuprofen in the last week or any condition that increases the likelihood of regular or sustained use during the intervention.\n* On proton pump inhibitors (Omeprazole, Esomeprazole, Lansoprazole, Rabeprazole, Pantoprazole) within the last one month on long acting non-steroidal anti-inflammatory drugs in the last month or any condition that increases the likelihood of regular use during the intervention.\n* Taking any prebiotic or probiotic supplementation within the last three months\n* Patients who are vegetarians or vegans","50 Years",{"count":63,"type":22},80,[25],"More than 7.4 million people in the UK are currently waiting for surgery. Behind that number are real people-patients preparing mentally and physically for procedures ranging from joint replacements to major heart and abdominal operations.\n\nThis research forms part of a broader strategy known as prehabilitation - preparing the body before surgery to improve outcomes afterward. For patients waiting for surgery, it represents a shift from passive waiting to active preparation.\n\nHeart surgery for bypass or valve replacements results in inevitable yet controlled trauma. It increases inflammation, stress hormones and immune system demand. The body then has to repair itself - quickly and efficiently. And here's the surprising part. Inside your gut live trillions of bacteria - called your gut microbiome. These bacteria help regulate inflammation, strengthen your immune system and protect against infection.\n\nThis randomised clinical trial is investigating a fascinating question:\n\nCan improving your gut microbiome through consumption of fibre before surgery help you recover faster, reduce time in ICU, shorten hospital stays, and lower complication rates? The placebo controlled trial will randomise 80 patients following eligibiilty checks to either 5g of prebiotic fibre\u002F300mg of magnesium (WellBiome) OR 5g of maltodextrin for a period of 6-8 weeks prior to surgery. Patient will provide blood, urine and faecal samples at baseline and upon admission for surgery, and two further blood samples at day 3 and 6 post operatively.\n\nFollowing surgery, patient outcomes will be assessed and compared between the experimental group (prebiotic fibre\u002Fmagnesium) and placebo group (maltodextrin). The investigators are focussing on the time spent in the intensive care unit, complications and overall hospital stay. By documenting and quantifying these the investigators can calculate the costs and any savings between the groups.",[30,67],"Cardiovascular Surgery",[69,70,71,72],"Cardiac surgery","Surgical outcomes","Nutritional prehabilitation","Microbiome","RECRUITING","2026-06-22",{"date":76,"type":45},"2026-06-23",{"date":78,"type":45},"2026-04-09",{"date":80,"type":22},"2026-12-18",{"name":82,"class":83},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100612357","european-study-of-the-briovad-heart-pump-for-advanced-heart-failure-100612357","NCT07252531","European Study of the BrioVAD Heart Pump for Advanced Heart Failure","European Investigation of the BrioVAD Left Ventricular Assist System for the Treatment of Refractory Left Ventricular Heart Failure","BRIOLIFE","INCLUSION CRITERIA:\n\n1. Patient is ≥ 18 years of age.\n2. Patient has a body surface area (BSA) ≥ 1.2 m2.\n3. Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.\n4. Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF \\\u003C 30% on inotropes or intra-aortic balloon pump (IABP).\n5. Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters\u002Fmin\u002Fm2, while not on inotropes, and also meets one of the following criteria:\n\n   1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or\n   2. Has advanced heart failure for at least 14 days and is dependent on an IABP for at least seven days.\n6. Patient has provided voluntary and informed consent.\n7. Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.\n\nEXCLUSION CRITERIA:\n\n1. Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis\u002Fsenile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and\u002For pericardial disease.\n2. Patient had a myocardial infarction within seven days before study enrollment.\n3. Patient had cardiothoracic surgery within 30 days before implant.\n4. Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.\n5. Patient has contraindications to warfarin anticoagulation.\n6. Patient has known hypo- or hypercoagulable state \\[e.g., disseminated intravascular coagulation (DIC)\\], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.\n7. Patient is on durable MCS (e.g., LVAD or RVAD).\n8. Planned need for durable or temporary RVAD support concomitant with LVAD implant.\n9. Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an IABP.\n10. Patient is on any form of pre-implant temporary MCS with a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or with plasma free hemoglobin \\> 40 g\u002FdL.\n11. Patient has a history of organ transplantation.\n12. Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.\n13. Patient has a platelet count \\\u003C 50 k\u002Fµl.\n14. Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) \\> 5 cm in diameter.\n15. Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.\n16. Patient has an uncontrolled systemic infection.\n17. Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin \\>1000 ug\u002FL.\n18. Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:\n\n    1. Total bilirubin \\> 3.0 mg\u002FdL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.\n    2. International normalized ratio (INR) ≥ 2.0 or PTT \\> 2.5 times control that is not related to anticoagulation therapy.\n    3. Glomerular filtration rate (GFR) \\\u003C 30 mL\u002F min\u002F1.73 m2 or need for renal replacement therapy.\n    4. Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.\n    5. Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1\u002FFVC \\\u003C 0.7 and FEV1 \\\u003C 40% predicted.\n    6. Mechanical ventilation for more than three days present at the time of study enrollment.\n    7. Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.\n    8. History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.\n    9. Symptomatic cerebrovascular disease and\u002For uncorrected carotid stenosis \\> 80%.\n    10. Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.\n    11. Pre-albumin \\\u003C 15 mg\u002FdL and\u002For albumin \\\u003C 2.5 g\u002FdL.\n19. Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.\n20. Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and\u002For insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.\n21. Patient is participating in an interventional clinical trial that may impact or confound the results of the BrioVAD Trial.",{"count":93,"type":22},60,[25],"This clinical investigation evaluates the safety and clinical performance of the BrioVAD Left Ventricular Assist System in patients with advanced, refractory left ventricular heart failure who require mechanical circulatory support.",[97,30],"Refractory Heart Failure",[99,100],"BrioVAD System","Left Ventricular Assist Device","2026-06-18",{"date":74,"type":45},{"date":104,"type":45},"2026-06-01",{"date":106,"type":22},"2029-01-31",{"name":108,"class":109},"BrioHealth BV","INDUSTRY",2,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100637342","early-phase-1-multi-organ-imaging-of-microvascular-and-metabolic-function-100637342","NCT07604207","Multi-organ Imaging of Microvascular and Metabolic Function","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* For patients with cardiovascular disease: Documented diagnosis of ischemic heart disease based on standard clinical, radiologic, and\u002For histopathologic criteria, as documented in the medical record; or a clinical nuclear cardiac stress PET test within 1 year.\n* For healthy subjects: No diagnosis of cardiometabolic disease, cancer, or other major disease within the past 5 years\n\nExclusion Criteria:\n\n* Contraindications to PET due to:\n\n  1. Research-related radiation exposure exceeding current MGB Radiology Department guidelines (i.e., 50 mSv in the prior 12 months);\n  2. Inability to lie comfortably on the bed inside the scanner;\n  3. Body weight \\> 300 lbs (weight limit of the scanner table);\n  4. Pregnancy or breastfeeding;\n* Individuals with fasting plasma glucose level of \\>200 mg\u002FdL;\n* Claustrophobia\n* Employed under the direct supervision of the PI conducting the research.",true,{"count":93,"type":22},[120],"EARLY_PHASE1","What if heart disease starts outside the heart? This research will study how to simultaneously assess brain and body physiology, how they are jointly related to heart function, and how their response to physical and mental stress differs in patients with heart disease.",[123,30],"Healthy Subjects (HS)","2026-05-18",{"date":126,"type":45},"2026-05-22",{"date":47,"type":22},{"date":129,"type":22},"2031-07",{"name":131,"class":52},"Massachusetts General Hospital",{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":53},"100586573","royal-jelly-as-a-strategy-to-modulate-inflammation-and-oxidative-stress-in-patients-with-systemic-arterial-hypertension-100586573","NCT06917131","Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension","Inclusion Criteria:\n\n* Diagnosis of stage 1 hypertension\n* Regular treatment for more than 6 months\n* No changes in medication doses during the last 3 months\n\nExclusion Criteria:\n\n* Autoimmune diseases\n* Infectious diseases\n* Diabetes\n* Chronic kidney disease\n* Liver disease\n* Cancer\n* AIDS\n* Pregnant women\n* Use of catabolic drugs or antibiotics\n* Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics\n* Habitual intake of royal jelly\n* Allergy to bee stings\n* Acute myocardial infarction (AMI)\n* Stroke (CVA)","75 Years",{"count":140,"type":22},34,[25],"The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.",[144,30,31],"Hypertension",[146,147,144,148],"royal jelly","inflammation","cardiovascular diseases","2026-05-14",{"date":151,"type":45},"2026-05-19",{"date":153,"type":45},"2024-09-18",{"date":155,"type":22},"2026-12-10",{"name":157,"class":52},"Universidade Federal Fluminense",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":170,"conditions":171,"keywords":177,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":53},"100568615","phase-2-palmitic-acid-and-human-microvascular-function-100568615","NCT06683534","Palmitic Acid and Human Microvascular Function","Use of Quercetin to Increase Resiliency to Palmitic Acid in the Human Microvasculature","Inclusion Criteria:\n\n* Obesity (BMI\\>30)\n* Aged 18-40 years\n* English Speaking\n\nExclusion Criteria:\n\n* BMI\\>60\n* Resting SBP ≥180 mmHg or DBP ≥ 110mmHg\n* Pregnancy or breastfeeding.\n* Prior history of myocardial infarction\n* Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)\n* Active mouth sores that affect the buccal mucosa.","40 Years",{"count":167,"type":22},40,[169],"PHASE2","The goal of this study is to learn how a supplement Quercetin can affect microvascular function.\n\nParticipants will:\n\n* give two blood draws of 5 mL each\n* have a camera placed under the tongue to take pictures of blood vessels\n* have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion\n\nResearchers will compare blood vessel function of those who take estrogen supplements to those who do not.",[172,173,174,30,175,176],"Microvascular Dysfunction","Microvasculature","Cardiovascular Diseases","Microvascular Health","Obesity and Overweight",[178,179],"Obesity","Supplement","2026-04-28",{"date":182,"type":45},"2026-04-29",{"date":47,"type":22},{"date":185,"type":22},"2030-12",{"name":187,"class":52},"Medical College of Wisconsin",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":197,"studyType":198,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":53},"100623190","identifying-risk-factors-and-predicting-future-health-outcomes-for-korean-patients-with-heart-and-blood-vessel-diseases-a-long-term-follow-up-study-100623190","NCT07393412","Identifying Risk Factors and Predicting Future Health Outcomes for Korean Patients With Heart and Blood Vessel Diseases: A Long-term Follow-up Study","PRIME (Precision Registry for Integrated Cardio-cerebrovascular Medicine & Evidence)","Inclusion Criteria:\n\nA patient who visited Samsung Medical Center due to cardiovascular and cerebrovascular disease.\n\nExclusion Criteria:\n\nA patient deemed unable to participate in the study based on the judgment of the medical staff.",{"count":196,"type":22},800000,"20 Years","OBSERVATIONAL","This study aims to establish a comprehensive, long-term clinical registry infrastructure for heart and brain vascular diseases (cardiovascular diseases and stroke) at Samsung Medical Center. In South Korea, these diseases are a leading cause of death, with a rapidly increasing burden due to an aging population and changing lifestyles. Despite this, there is a lack of large-scale, systematic data specifically focused on the long-term clinical course and unique characteristics of Korean patients.\n\nThe central hypothesis of this study is that the establishment of a standardized registry infrastructure-integrating both retrospective (historical) and prospective (future) data collection-will provide a more accurate and comprehensive understanding of the natural history and risk factors of heart and brain vascular diseases in the Korean population than currently available fragmented data. By combining existing medical records with ongoing patient follow-up, this infrastructure will serve as a critical scientific platform for developing personalized prevention and precision medicine strategies.\n\nBy building this organized data collection system, the study will:\n\nConstruct a robust infrastructure to collect uniform, high-quality clinical data, encompassing both past medical history (retrospective) and future clinical progress (prospective) from a large population of Korean patients.\n\nMonitor long-term health outcomes and the progression of diseases by tracking patients over many years.\n\nAnalyze the interaction between various risk factors and patient outcomes to identify population-specific patterns.\n\nCreate a scalable platform that can integrate advanced technologies, such as multi-omics and digital health tools, for future research.\n\nUltimately, this integrated registry infrastructure is expected to provide the essential scientific evidence needed to optimize clinical guidelines and improve the long-term quality of life for patients with heart and brain vascular diseases in Korea.",[30,201],"Cerebro Vascular Disease","2026-04-23",{"date":180,"type":45},{"date":205,"type":45},"2026-02-02",{"date":207,"type":22},"2040-12-31",{"name":209,"class":52},"Samsung Medical Center",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":217,"targetDuration":219,"studyType":198,"phases":4,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":53},"100635008","study-on-construction-of-whole-lifecycle-cohort-big-data-management-and-clinical-prognosis-of-cardio-renal-metabolic-ckm-syndrome-100635008","NCT07547098","Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome","CKM-LCBP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.\n* Cardiovascular disease, kidney disease, metabolic disease, or key examination\u002Flaboratory information supporting CKM phenotyping.\n* Willingness to participate and provision of written informed consent.\n* Ability to complete baseline assessment and follow-up.\n* Full civil capacity and ability to understand study information.\n\nExclusion Criteria:\n\n* Refusal to provide written informed consent.\n* Severe psychiatric disease or cognitive impairment precluding participation.\n* End-stage disease with expected survival less than 1 year.\n* Long-term absence more than 6 months preventing reliable follow-up.\n* Participation in another clinical study that may interfere with endpoint adjudication.\n* Missing key fields preventing linkage of examinations, imaging, and outcomes.",{"count":218,"type":22},8000,"5 Years","This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and\u002For metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.",[30,222,223,224],"Chronic Kidney Disease","Metabolic Diseases","Cardiovascular-kidney-metabolic Syndrome",[226,227,228,229],"CKM syndrome","Cardiovascular-Kidney-Metabolic","Patient registry","Real-world data","2026-04-19",{"date":202,"type":45},{"date":233,"type":45},"2026-03-01",{"date":235,"type":22},"2031-02-28",{"name":237,"class":52},"First Affiliated Hospital of Fujian Medical University",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":53},"100629721","heart-institute-biorepository-hibr-for-pediatric-heart-disease-100629721","NCT07478354","Heart Institute BioRepository (HIBR) for Pediatric Heart Disease","HIBR","Inclusion Criteria\n\n* Any fetus, child or adult at risk of or diagnosed with Pediatric Heart Disease (PHD) or Cardiovascular Disease (CVD)\n* Any HI patient, including the following types of encounters: Surgery or Cardiac Catheterization or Advanced Imaging encounters, Inpatient, including Cardiology service, consultation patients and Fetal Delivery, and Outpatient, including all HI-associated clinics and consultation services\n* Any female carrying a fetus with a suspected cardiac diagnosis\n\nExclusion Criteria\n\n* Legal guardian unauthorized to consent\n* Families who choose Palliative care during pregnancy",{"count":246,"type":22},5000,"The purpose of this protocol is to redefine the Heart Institute BioRepository (HIBR) to facilitate Investigator-initiated and programmatic basic, translational, clinical and outcomes research. For the purposes of this protocol, \"tissue\" will refer to any gross specimen obtained from a patient, including but not limited to blood, cardiovascular tissue, urine, saliva, and other tissues and bodily fluids, including explanted non-human prosthetics or grafts. In this context, \"tissue\" is synonymous with \"sample\" or \"specimen.\" A \"BioRepository\" functions to systematically collect, maintain and govern tissue specimens.",[30],[250,251],"cardiovascular disease","Pediatric Heart disease","2026-04-02",{"date":254,"type":45},"2026-04-08",{"date":256,"type":45},"2012-01-27",{"date":258,"type":22},"2050-01-01",{"name":260,"class":52},"Children's Hospital Medical Center, Cincinnati",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":281,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100632650","vdyne-transcatheter-tricuspid-valve-replacement-study-to-evaluate-safety-and-clinical-efficacy-in-patients-with-symptomatic-severe-tricuspid-valve-regurgitation-trivita-pivotal-trial-100632650","NCT07516444","VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)","VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation","TRIVITA","Inclusion Criteria:\n\n* Age ≥18 years old\n* Subject is willing and able to comply with all study evaluations and provide consent\n* Subject must agree not to participate in any other clinical trial for a period of one year following index procedure\n* New York Heart Association (NYHA) Functional Class II, III, or IV and ambulatory\n* At least severe symptomatic tricuspid regurgitation.\n* Despite adequate and Optimized Medical Therapy (OMT), subject has signs and symptoms from TR, or prior heart failure hospitalization from TR\n* Heart team determines that the subject is appropriate for transcatheter tricuspid valve replacement\n* Functional and\u002For degenerative TR graded as at least severe\n\nExclusion Criteria:\n\n* Subject unable or unwilling to comply with study required testing and follow-up visits\n* Subject is currently participating in another clinical trial (drug, biologic, or device) that has not yet completed its primary endpoint or is likely to interfere with this study\n* Pregnant, lactating subjects, and \u002For those who plan pregnancy in the period up to one year following index procedure.\n* Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anticoagulation, etc.) which cannot be adequately managed medically\n* Life expectancy ≤12 months due to non-cardiac comorbidities\n* Current IV Drug user (must be free from drug abuse for ≥1 year)\n* Subject unable or unwilling to provide written, informed consent before study enrollment\n* Tricuspid valve anatomy (cardiac and vascular) that is not suitable for the VDyne System\n* Hypersensitivity to metals (such as nickel or titanium)\n* Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne valve (e.g., valve replacement, edge to edge repair, etc.)\n* Severe valvular heart disease using established echocardiographic criteria requiring intervention other than the tricuspid valve\n* Known significant intracardiac shunt (e.g., septal defect).\n* Cerebrovascular accident (stroke, TIA) within 90 days of treatment procedure\n* Severe lung disease (severe COPD) or continuous use of home oxygen or oral steroids\n* Acute myocardial infarction (AMI) within 30 days of SSC determination of eligibility\n* Leukopenia, chronic anemia (Hgb \\\u003C 9 g\u002FdL), current thrombocytopenia (platelets \\\u003C70\u002FmcL), history of bleeding diathesis, or coagulopathy\n* Unwilling to receive blood products\n* Deep vein thrombosis and\u002For pulmonary embolism in the last 6-months",{"count":270,"type":22},730,[25],"Pivotal trial to evaluate the safety and clinical efficacy of the VDyne System for the treatment of symptomatic severe or greater tricuspid regurgitation.",[274,275,30,276,277,278,279,280],"Tricuspid Valve Regurgitation","Tricuspid Valve Disease","Heart Valve Diseases","Tricuspid Valve Insufficiency","Severe Heart Valve Disease","Randomized Controlled Trial (RCT)","Symptomatic Tricuspid Regurgitation",[282,267,283,284],"VDyne","TRIVITA Pivotal","Tricuspid Regurgitation","2026-03-31",{"date":254,"type":45},{"date":288,"type":22},"2026-06",{"date":290,"type":22},"2036-06",{"name":292,"class":109},"VDyne, Inc.",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":303,"conditions":304,"keywords":308,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":53},"100623816","assessment-and-prediction-of-cardiovascular-health-and-disease-risk-using-wearable-biometrics-100623816","NCT07401550","Assessment and Prediction of Cardiovascular Health and Disease Risk Using Wearable Biometrics.","Assessment and Prediction of Cardiovascular Health and Disease Risk Using Longitudinal Wearable Biometrics: a Prospective Cohort Study.","BEACON-HEART","Inclusion Criteria:\n\n* Adults aged 18 years, or older\n* Internet access\n* Possession of a smartphone compatible with the Fitbit mobile app\n\nExclusion Criteria:\n\n* Pregnancy\n* Unstable medical condition\n* Inability to provide informed consent\n* Mental or cognitive impairment precluding adherence to study protocol\n* Smartwatch cannot be worn, (e.g., allergic reactions), or cannot be worn in accordance with manufacturer guidelines (e.g., amputation, dark tattoos at wrist)",{"count":302,"type":22},100,"This prospective, observational cohort study will evaluate the associations between wearable-derived biometrics and cardiovascular health, quantified by the American Heart Association's Life's Essential 8 framework, as well as related cardiovascular risk factors. The study aims to determine whether wearable biometrics can support the assessment of cardiovascular health and cardiovascular disease risk, both when used in isolation and in combination with point-of-care assessments.",[30,305,306,307],"Cardiovascular Disease Prevention","Cardiovascular Disease Risk Factor","Coronary Artery Disease (CAD)",[309,310,311,250,312,313,314,315,316,317,318,319],"wearables","wearable devices","cardiovascular health","wearable technology","fitbit","fitabase","remote monitoring","cardiovascular disease prevention","cardiovascular risk reduction","digital biomarker","coronary artery disease","2026-02-03",{"date":322,"type":45},"2026-02-10",{"date":324,"type":45},"2025-12-09",{"date":326,"type":22},"2026-12",{"name":328,"class":52},"University College Dublin",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":138,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100621936","effects-of-sweetener-consumption-on-risk-factors-for-heart-disease-in-prediabetic-subjects-100621936","NCT07377097","Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects","Effects of Sweetener Consumption on Risk Factors for Heart Disease","Sweetheart","Inclusion Criteria:\n\n* Presence of prediabetes (HbA1c 5.7-6.4% or glucose after oral glucose tolerance test 140 to 199 mg\u002FdL)\n* Written informed consent available\n\nExclusion Criteria:\n\n* Inability to communicate sufficiently in the required language\n* Dementia or other significantly cognitively impairing condition\n* Current pregnancy or breastfeeding\n* Other severe internal, neurological, or psychiatric condition\n* History of gout\n* History of gallstones \u002F diagnosis of cholelithiasis",{"count":63,"type":22},[25],"The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes. Prediabetes is a condition characterized by blood sugar levels that are elevated above normal but not yet meeting the criteria for type 2 diabetes. This condition markedly increases the risk of progressing to type 2 diabetes, which in turn can lead to complications including cardiovascular diseases.\n\nArtificial sweeteners such as saccharin and sucralose, as well as natural sugar substitutes like erythritol, are increasingly used as alternatives to sugar and are recommended for individuals at cardiometabolic risk - including overweight individuals, patients with prediabetes, or diabetics - to help reduce caloric intake. Recent literature has reported possible negative associations between artificial sweeteners and blood sugar regulation in healthy subjects (1). Additionally, effects on various blood cells have been observed. For example, erythritol has been shown to alter platelet function leading to increased reactivity in healthy study participants following consumption (2).\n\nHowever, the impact of alternative sweeteners on metabolic processes and their effects on blood coagulation in patients with prediabetes-a population at increased risk-has not been systematically studied. In this planned interventional study, 80 patients meeting laboratory criteria for prediabetes will be randomly assigned to one of four groups, each receiving a different intervention for two weeks: saccharin, sucralose, erythritol, or a control group receiving water. The doses reflect the acceptable daily intake or known doses that are considered safe.\n\nAfter enrollment, participants will visit the study center 2 times: before starting the intervention and after completing the intervention. During these visits, biological samples such as blood, urine, and stool will be collected to study metabolism, gut bacteria, immune and blood cell function. Tests will include an oral glucose tolerance test, coagulation tests, and additional blood analyses. Additionally, participants will wear a glucose monitor to track blood sugar fluctuations during the intervention.\n\nThe investigators hypothesize that consumption of alternative sweeteners negatively affects blood sugar regulation and insulin sensitivity in patients with prediabetes. Furthermore, this study will explore how the candidate sweeteners influence the gut microbiome, blood cells and other metabolic factors in this population.",[341,342,343,344,345,346,347,30,348,349,350],"Prediabetic State","Metabolic Syndrome","Insulin Resistance","Thrombosis","Hypercoagulable State","Cardiovascular (CV) Risk","Cardiovascular Risk Factors","Prediabetes","Prediabetes \u002F Type 2 Diabetes","Sweeteners","2026-01-22",{"date":353,"type":45},"2026-01-29",{"date":355,"type":22},"2026-01-05",{"date":357,"type":22},"2026-11-01",{"name":359,"class":52},"Charite University, Berlin, Germany",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":165,"maxAge":4,"enrollmentInfo":366,"targetDuration":368,"studyType":198,"phases":4,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":110},"100615617","study-protocol-10-year-follow-up-of-patients-screened-for-cardiovascular-risk-by-the-all-with-heart-association---development-of-a-morocco-specific-risk-score-100615617","NCT07294937","Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk by the \"All With Heart\" Association - Development of a Morocco-Specific Risk Score","Inclusion Criteria:\n\n* Adults aged 40 years or older at the time of the initial screening (2010-2012).\n* Individuals who participated in the cardiovascular risk screening campaign conducted by the \"All with heart\" Association between 2010 and 2012 in the Greater Casablanca region.\n* Moroccan nationality.\n* Participants or family members who provide written informed consent for participation in the 10-year follow-up study.\n\nExclusion Criteria:\n\n* Individuals who refuse to participate in the follow-up study.\n* Participants who have moved and cannot be reached by phone, WhatsApp, or SMS.\n* Participants who died from non-cardiovascular causes.\n* Non-Moroccan participants.",{"count":367,"type":22},10000,"1 Day","Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and their prevalence is steadily increasing in Morocco. Between 2010 and 2012, the \"All with heart\" Association conducted a large-scale cardiovascular screening campaign in the Greater Casablanca region, involving more than 10,000 adults aged over 40 years. This 10-year follow-up study aims to evaluate long-term cardiovascular outcomes and to develop a Morocco-specific cardiovascular risk score. Follow-up data will be collected through phone calls, WhatsApp, or SMS with participants or their families to document cardiovascular deaths, myocardial infarctions, and strokes. Statistical analyses, including survival analysis and multivariate logistic regression, will be used to identify significant risk factors and to construct a predictive risk model tailored to the Moroccan population. The study received a favorable opinion from the Rabat Ethics Committee. Written informed consent will be obtained from all participants or their families prior to data collection. The findings are expected to enhance understanding of cardiovascular risk evolution in Morocco and to provide a validated, population-specific risk score to support prevention and patient management strategies.",[30],"2025-12-15",{"date":373,"type":45},"2025-12-19",{"date":375,"type":45},"2025-10-01",{"date":377,"type":22},"2026-10",{"name":379,"class":52},"Moroccan Society of Cardiology",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":388,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":398,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":110},"100601493","ambient-air-and-noise-effect-on-cardiovascular-health-risk-and-lifestyle-intervention-to-attenuate-it-metsgreen-100601493","NCT07111208","Ambient Air and Noise Effect on Cardiovascular Health Risk and Lifestyle Intervention to Attenuate It (METSGREEN)","Noise and\u002For Ultrafine Particulate Matter Induced Cerebral and Cardiovascular Damage: Experimental and Epidemiological Studies (MARKOPOLO) and Lifestyle Intervention to Attenuate Cardiovascular Health Risk (METSGREEN)","METSGREEN","Inclusion Criteria:\n\n* Age 45-64 years\n* Residence in Kaunas City\n* Presence of metabolic disorder indicators (e.g., increased waist circumference and\u002For elevated blood pressure)\n* Willingness to participate and provide written informed consent\n* Agreement to wear a wristband sensor continuously for 7 days\n\nExclusion Criteria:\n\n* Unstable angina or cardiomyopathy\n* Blood pressure \\>160\u002F110 mmHg\n* Neurological diseases or limited mobility\n* Presence of a cardiac pacemaker\n* Pregnancy\n* Alcohol dependence","45 Years","64 Years",{"count":391,"type":22},180,[25],"This study, combining both an observational study and an interventional clinical trial, aims to assess how exposure to ultrafine particulate matter (PM0.1) and noise pollution affects the risk of cardiovascular diseases and metabolic disorders in 45-64-year-old residents of Kaunas City, and whether lifestyle interventions-specifically physical activity in green spaces and the Mediterranean diet-can help reduce these risks.\n\nIn the observational part, approximately 1,000 randomly selected 45-64 years men and women living in private households will complete an anonymous online health and lifestyle questionnaire. The clinical interventional trial will include 180 participants, who agreed to participate in the clinical study and, who meet specific health criteria. The main questions the study seeks to answer are: whether increased exposure to PM0.1 and noise is linked to higher cardiovascular and metabolic risk; and whether short-term healthy lifestyle changes can improve biological markers associated with these conditions.\n\nParticipants in the clinical trial will be randomly assigned to one of three groups: (1) control group continuing usual habits, (2) physical activity group at least 30-minute daily walks in green spaces, or (3) group adherence to a Mediterranean diet. They will have two visits to the clinic for health surveys:\n\n* Wear a wristband sensor for 7 days to monitor physical activity, heart rate, and sleep quality\n* Visit a clinic on Day 1 and Day 8 for measurements (blood pressure, waist circumference, body composition) and give blood samples for biomarker analysis.\n\nThis research will provide new evidence on environmental health risks and practical recommendations for reducing the burden of metabolic and cardiovascular diseases.",[30,342,395,396,397],"Air Pollution Exposure","Environmental Exposure","Health Behavior Change",[399,400,401,402,403,404,405],"ultrafine particles","noise pollution","cardiovascular risk","metabolic syndrome","physical activity","Mediterranean diet","environmental exposure","2025-11-21",{"date":408,"type":45},"2025-11-28",{"date":410,"type":45},"2025-10-24",{"date":412,"type":22},"2028-12",{"name":414,"class":52},"Regina Grazuleviciene",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":197,"maxAge":4,"enrollmentInfo":422,"targetDuration":219,"studyType":198,"phases":4,"briefSummary":424,"conditions":425,"keywords":430,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":53},"100612037","validating-integrative-multi-omics-approaches-in-metabolic-syndrome-related-diseases-100612037","NCT07248371","Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases","Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases: A Step Towards Precision Medicine","Inclusion Criteria:\n\n* Individuals (male or female) aged 20 years or older\n* Willing and able to provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis\n* Individuals currently undergoing active cancer treatment\n* Recipients of any organ transplantation\n* Patients diagnosed with dementia",{"count":423,"type":22},6266,"This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and without metabolic syndrome, the research seeks to determine which biological factors predict disease progression and how these insights can inform precision prevention and treatment strategies for metabolic disorders.",[426,427,30,222,428,429],"Metabolic Syndrome (MetS)","Obesity & Overweight","Nonalcoholic Fatty Liver Disease","Healthy",[342,431,432,433,434,435,72,436],"Multi-Omics","Precision Medicine","Metabolomics","Genomics","Transcriptomics","Machine Learning","2025-11-18",{"date":439,"type":45},"2025-11-25",{"date":441,"type":45},"2025-06-09",{"date":443,"type":22},"2035-09-30",{"name":445,"class":52},"Chang Gung Memorial Hospital",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":456,"conditions":457,"keywords":458,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":4},"100611242","data-donation-model-for-inclusive-cardiovascular-prevention-using-the-train-health-platform-100611242","NCT07238036","Data Donation Model for Inclusive Cardiovascular Prevention Using the TRAIN Health Platform","The Data Donation Model: Redefining Citizen Participation in Inclusive Cardiovascular Prevention and Care","DDM-TRAIN","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Access to a smartphone, tablet, or computer with internet connection.\n* Ability to provide electronic informed consent (in Dutch or with supported translation).\n* Willingness to contribute lifestyle, health, and\u002For wearable data through the TRAIN Health Awareness Platform.\n* Optional: interest in participating in the 12-week TRAIN Heart Journey for personalised lifestyle feedback.\n\nExclusion Criteria:\n\n* Inability to provide informed consent, even with support.\n* Severe cognitive or psychiatric impairment limiting safe participation.\n* Inability to use digital devices, even with assistance.\n* Concurrent participation in another behavioural or interventional study that could interfere with data collection.",{"count":455,"type":22},450,"Cardiovascular disease (CVD) is the leading cause of death in the Netherlands and worldwide. While prevention strategies have improved, many population groups, including women, individuals with a migration background, and people with lower socioeconomic status, remain underrepresented in cardiovascular research and prevention programs. As a result, current risk prediction models and lifestyle recommendations are based largely on homogeneous datasets that do not reflect real-world diversity. This structural imbalance limits the generalisability of evidence and contributes to persistent health disparities.\n\nThe Data Donation Model (DDM) aims to address this gap by introducing a citizen-led, transparent, and participatory approach to data sharing for cardiovascular prevention and health research. In this model, individuals voluntarily contribute their lifestyle, behavioural, and wearable\u002Fapp data for research while maintaining full control over consent and use. The DDM incorporates dynamic electronic consent, granular sharing options, and transparency dashboards that allow participants to view how their data contribute to ongoing research projects. This participatory design strengthens trust, autonomy, and inclusiveness in data governance.\n\nThis study evaluates the feasibility, inclusiveness, and acceptability of implementing the DDM at scale within the general population. It forms the pilot phase of a broader national data donation infrastructure coordinated by Amsterdam UMC in collaboration with the TRAIN Health Awareness Platform (technical partner) and community organisations. Approximately 450 participants will take part in this first phase, with future expansion planned up to 10,000 citizens.\n\nParticipants can connect any wearable device or health app (such as a smart ring, smartwatch, or fitness tracker) to the TRAIN platform and complete short digital questionnaires on lifestyle, sleep, stress, and wellbeing. All participants can donate data for up to 5 years, with the freedom to stop or modify consent at any time. An optional 12-week TRAIN Heart Journey provides guided feedback on physical activity, stress, and recovery patterns, but participation in this module is not required for data donation.\n\nThe main outcomes are (1) feasibility and acceptability of the DDM (recruitment, retention, adherence, and user satisfaction), (2) inclusiveness of participation across demographic groups, and (3) trust and engagement with science and data governance. Secondary outcomes include behavioural and physiological changes (activity, sleep, stress) and self-efficacy. Exploratory analyses will evaluate long-term engagement and, for consenting participants, linkage with official mortality data from Statistics Netherlands (CBS).\n\nThe findings will inform future national strategies for equitable, citizen-driven cardiovascular prevention and contribute to developing inclusive guidelines based on real-world data from diverse populations.",[30],[459,460,461,462,463,464,465,466,467,468,469,470,471,472],"cardiovascular prevention","data donation","citizen science","health equity","participatory research","digital health","wearable data","lifestyle monitoring","trust in science","inclusiveness","population health","prevention research","FAIR data","Open Science","2025-11-15",{"date":475,"type":45},"2025-11-20",{"date":477,"type":22},"2026-01",{"date":479,"type":22},"2027-04-01",{"name":481,"class":52},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":53},"100604300","pulmonary-arterial-hypertension-and-associated-cardiovascular-disease-detection-using-artificial-intelligence-100604300","NCT07147725","Pulmonary Arterial Hypertension and Associated Cardiovascular Disease Detection Using Artificial Intelligence","PULSAR","Inclusion Criteria:\n\n* Age 18 years or above\n* Able to give informed consent\n* Attending for echocardiography at Imperial College NHS Trust\n\nExclusion Criteria:\n\n• Any chest wound, skin pathology or other feature that would prohibit routine stethoscope examination",{"count":490,"type":22},1000,"Cardiovascular disease (CVD) is a leading global cause of morbidity and mortality and excessive healthcare expenditures. Pulmonary hypertension (PH) represents an insidious and progressive subset of CVD affecting an estimated 1% of the general population, increasing to up to 10% in the population over the age of 65. Recent advancements in artificial intelligence (AI) have shown promise in transforming PH diagnosis by enabling the analysis of complex physiological data. Specifically, AI algorithms applied to electrocardiography (ECG) and phonocardiography (PCG) waveforms captured through novel medical devices, such as smart stethoscopes, have demonstrated potential in detecting PH and other cardiovascular conditions with high sensitivity and specificity.\n\nDespite the promising capabilities of AI algorithms, a significant barrier to their clinical implementation is the lack of high-quality, prospectively collected datasets for validation. Many existing AI algorithms have been trained on retrospective data, which may not capture the variability and complexity of real-world clinical scenarios. This limitation raises concerns about the generalisability and reliability of AI predictions across diverse patient populations.\n\nTherefore, there is a critical need for prospective validation studies to assess the performance of AI algorithms in realworld settings, ensuring their accuracy and applicability before widespread clinical deployment. Imperial College London's Health Impact Lab (Hi Lab) and collaborators continue to develop artificial intelligence (AI) algorithms that use cardiac waveforms to predict cardiovascular disease (CVD), including pulmonary hypertension (PH). The performance of these algorithms requires validation on prospectively collected patient data (waveforms) - where the ground truth for the algorithms under investigation is recorded during routine echocardiography as part of clinical care. This study aims to prospectively collect a large dataset of cardiovascular ECG and PCG data, along with corresponding gold-standard echocardiography findings. This dataset will be used to validate AI algorithms for important CVD, such as pulmonary hypertension enhancing their reliability and clinical applicability.",[493,30],"Pulmonary Hypertension",[495,496,497,498],"Artificial Intelligence","Algorithms","Digital Health","Cardiology","2025-09-22",{"date":501,"type":45},"2025-09-23",{"date":375,"type":22},{"date":504,"type":22},"2027-08-01",{"name":506,"class":52},"Imperial College London",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":18,"minAge":514,"maxAge":515,"enrollmentInfo":516,"targetDuration":518,"studyType":198,"phases":4,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":110},"100561870","the-hellenic-thoracic-society-initiative-for-cpd-and-cvd-100561870","NCT06595784","The HELlenic Thoracic Society Initiative for CΟPD and CVD","HELICOPD","Inclusion criteria\n\nPatients should cumulatively meet the following three (3) criteria to be enrolled in the study:\n\n1. To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease)\n2. Adults aged \\>35 years at the time of inclusion in the study,\n3. With signed informed consent for their participation in the study. Exclusion criteria Patients with the below limitations are not eligible to participate in the study\n\nPatients:\n\n1. Without at least one cardiovascular comorbidity,\n2. With history of lung cancer\n3. With any other active malignancy and undergoing treatment (chemotherapy\u002Fradiotherapy\u002Fimmunotherapy)\n4. With any thoracic or abdominal surgery planned during study follow-up period\n5. With participation in any COPD-related interventional study at study entry or during study duration.\n6. Without signed informed consent for their participation in the study.","35 Years","99 Years",{"count":517,"type":22},900,"24 Months","COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.",[521,30],"Chronic Obstructive Pulmonary Disease (COPD)",[523,524,525,526,527,528],"Chronic obstructive pulmonary disease","COPD","Cardiovascular disease","CVD","Protocol","Real-World Data","2025-09-09",{"date":531,"type":45},"2025-09-10",{"date":533,"type":45},"2024-10-15",{"date":377,"type":22},{"name":536,"class":52},"Hellenic Thoracic Society",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":546,"studyType":198,"phases":4,"briefSummary":547,"conditions":548,"keywords":554,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":53},"100596262","cardiovascular-kidney-metabolic-syndrome-in-shanghai-zicitizens-100596262","NCT07043166","Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens","Epidemiological Survey and Follow-up of Cardiovascular-Kidney-Metabolic Diseases Among Adults in Shanghai","Inclusion Criteria:\n\n1. The 4,094 residents of Shanghai communities who have been enrolled in the STONE cohort.\n2. Individuals who completed the baseline questionnaire survey, physical examination, and related clinical tests between 2016 and 2017, with complete data records.\n3. Willingness to participate in this follow-up study and provision of informed consent.\n\nExclusion Criteria:\n\n1. Participants who have moved away from their original community and have been living elsewhere for more than two years.\n2. Participants whose contact information has changed or become invalid, resulting in loss of contact (those who remain uncontactable after three attempts to reach out).",{"count":545,"type":22},4094,"10 Years","The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants.\n\nThe study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, participants will be categorized based on CKM staging. The follow-up phase will continue until 2035.",[342,549,176,144,550,551,552,553,30,224],"Diabetes","Dyslipidemia","Thyroid Diseases","Bone Metabolism Disorder","Chronic Kidney Disease(CKD)",[555,556,557,558,559,560],"Cardiovascular-Kidney-Metabolic Syndrome","metabolic disorders","screening","risk factor","evaluation","prediction","2025-08-31",{"date":563,"type":45},"2025-09-08",{"date":565,"type":45},"2025-07-01",{"date":567,"type":22},"2035-12-31",{"name":569,"class":52},"Shanghai Changzheng Hospital",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":577,"minAge":19,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":580,"briefSummary":581,"conditions":582,"keywords":585,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":53},"100578484","adapting-a-stress-management-intervention-to-reduce-cardiovascular-disease-risk-100578484","NCT06811896","Adapting a Stress Management Intervention to Reduce Cardiovascular Disease Risk","Adapting and Piloting a Stress Management Intervention to Reduce Cardiovascular Disease Risk Among Women Living With HIV","Inclusion Criteria:\n\n1. cis-gender females at least 18 years of age\n2. HIV-seropositive and a patient of the recruiting clinic\n3. English speaking\n\nExclusion Criteria:\n\n1. severe mental illness\n2. not being willing able to provide informed consent\n3. not willing or able to attend study visits","FEMALE",{"count":579,"type":22},48,[25],"Women living with HIV have 2-4x higher risk for cardiovascular disease compared to women without HIV, with women living with HIV in the Southern US being particularly at risk. While an increased prevalence of traditional risk factors (e.g., hypertension, diabetes, and obesity) partially explain this risk, evidence suggests that increased exposure to structural and social stressors (e.g., poverty, discrimination, and stigma) among women living with HIV in the South negatively contribute to cardiovascular disease disparities through their impact on stress. The Stress Management and Resiliency Training (SMART) program is an effective, evidence-based intervention proven to improve resiliency to environmental stressors and reduce the physiologic responses to stress which contribute to cardiovascular disease. While the SMART program has demonstrated efficacy in a wide range of populations and settings, it has not been designed for or tested among women living with HIV in the South, where unique cultural and faith-based context may diminish the uptake and value of the intervention to mitigate cardiovascular disease risk. The purpose of this study is to adapt the evidence-based SMART program in consideration of the needs and contexts of women living with HIV in the Southern US and pilot the adapted intervention to establish the feasibility, acceptability, and preliminary impact of the adapted intervention to reduce stress and mitigate cardiovascular disease risk among this population.",[583,584,30],"Stress","Blood Pressure",[586,587,588,589,401],"stress","resiliency","meditation","blood pressure","2025-08-25",{"date":592,"type":45},"2025-08-26",{"date":594,"type":45},"2025-05-14",{"date":596,"type":22},"2028-04",{"name":598,"class":52},"University of Alabama at Birmingham",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":606,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":608,"conditions":609,"keywords":613,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":623},"100603207","a-multi-center-study-on-artificial-intelligence-based-quantitative-evaluation-of-echocardiography-100603207","NCT07133516","A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography","MAIQUEE","Inclusion Criteria:\n\n1. Age ≥18 - 80 years;\n2. Types of diseases (8 in total, 200 cases each):\n\n   1. Normal heart\n   2. Coronary heart disease (with segmental thinning and abnormal movement)\n   3. Valve disease (valve stenosis or reflux)\n   4. Hypertensive heart disease\n   5. Atrial fibrillation\n   6. Heart failure\n   7. Dilated cardiomyopathy\n   8. Hypertrophic cardiomyopathy\n\nExclusion Criteria:\n\n1. Patients with congenital heart disease\n2. Patients with poor image quality",{"count":607,"type":22},1600,"This project aims to collaborate with multiple medical institutions to verify the accuracy, stability, and clinical application value of AI algorithms in echocardiographic quantitative measurement through multi-center clinical research. Specific objectives include:\n\n1. Compare the automatic measurement results of AI with the manual measurement data from physicians of different levels, and analyze the measurement deviation and consistency of AI in key parameters such as intracardiac diameter, volume, and function.\n2. Investigate whether AI-assisted measurement can significantly reduce echocardiogram analysis time and optimize clinical workflows. Through multi-center data validation, establish a standardized reference system for AI ultrasound measurement, promote the promotion and application of AI technology in medical institutions at all levels, and reduce diagnostic differences between different hospitals and physicians.\n3. Exploring the application of AI in special cases: Assessing the measurement stability of AI algorithms in complex cases (such as cardiomyopathy, valvular disease, coronary heart disease, etc.), and optimizing AI models to meet broader clinical needs.",[610,611,30,612],"Artificial Intelligence (AI)","Artificial Intelligence (AI) in Diagnosis","Echocardiography",[610,611,30,612],"2025-08-18",{"date":616,"type":45},"2025-08-21",{"date":618,"type":45},"2025-07-22",{"date":620,"type":22},"2026-07-31",{"name":622,"class":52},"First Hospital of China Medical University",37,{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":18,"minAge":197,"maxAge":20,"enrollmentInfo":631,"targetDuration":4,"studyType":23,"phases":632,"briefSummary":633,"conditions":634,"keywords":636,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":53},"100600480","cardio-fit2-impact-of-a-cardiac-rehabilitation-program-in-patients-with-cardiovascular-disease-100600480","NCT07098039","Cardio-Fit2: Impact of a Cardiac Rehabilitation Program in Patients With Cardiovascular Disease","Cardio-Fit2","Inclusion Criteria:\n\n1. Patients between the ages of 20 and 80.\n2. Have suffered an acute event or have chronic cardiovascular disease with decreased\u002Flimited functional capacity.\n3. Reside in the provinces of Cuenca, Toledo, or Albacete.\n4. Willingness to participate voluntarily and acceptance of the conditions.\n5. Must report the ability to access new technologies.\n\nExclusion Criteria:\n\n1. Have a physical or mental condition that prevents participation.\n2. Inability to adhere to the entire program, as reported in the initial consultation.\n3. Are outside the age criteria defined above.",{"count":93,"type":22},[25],"Cardiovascular diseases (CVD) are the main cause of morbidity and mortality in the world, being responsible for 17.9 million deaths annually, according to the World Heart Federation (WHF), which represents a significant social and health cost both due to direct expenses derived from admissions and diagnostic-therapeutic methods, as well as indirect expenses secondary to work incapacity, disability and loss of autonomy that this generates. Although advanced diagnostic and therapeutic techniques have been incorporated in recent years in the acute phase of ischemic heart disease, interventions during hospitalization and after hospital discharge remain insufficient in terms of secondary prevention, a paradoxical fact, since increasingly, the available evidence, as well as the recommendation guidelines, focus on the modification of lifestyle habits and control of cardiovascular risk factors (CVRF), fundamental pillars of cardiac rehabilitation programs (PRC) as a preventive measure both in the appearance of new adverse events and in the reduction of disease progression and improvement of the functional capacity of the patient. Cardiac rehabilitation (CR) was defined by the World Health Organization (WHO) in the 1960s as \"the set of activities necessary to ensure that heart patients have an optimal physical, mental and social condition, allowing them to occupy, by their own means, as normal a place as possible in society.\" The scientific evidence is more than consistent regarding the benefits that multidisciplinary CRP provides in terms of cardiovascular mortality and quality of life (QoL) of our patients and how these results are maintained despite changes in patient characteristics and risk, or the incorporation of new pharmacological treatments. Therefore, if we deprive our patients of these therapies, we are indirectly acting negatively on their cardiovascular prognosis, especially within the field of ischemic heart disease, although it is increasingly being extended to other areas of Cardiology such as heart failure (HF), pulmonary hypertension (PH), valvular disease,7 etc. So much so that it is already included in the latest clinical practice guidelines of the main scientific societies at European and American level, establishing participation in a CR program after acute coronary syndrome or coronary revascularization and those patients with HF as a \"level of recommendation I evidence A\"",[30,635],"Cardiac Rehabilitation",[637,148,309],"cardiac rehabilitation","2025-07-24",{"date":640,"type":45},"2025-08-01",{"date":642,"type":22},"2025-09-01",{"date":644,"type":22},"2025-12-31",{"name":646,"class":52},"Hospital Virgen de la Luz",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":655,"targetDuration":657,"studyType":198,"phases":4,"briefSummary":658,"conditions":659,"keywords":660,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":53},"100477737","swiss-secondary-prevention-and-rehabilitation-registry-100477737","NCT05500859","Swiss Secondary Prevention and Rehabilitation Registry","Swiss Secondary Prevention and Rehabilitation Registry: SwissPR","SwissPR","Inclusion Criteria:\n\n* Participation in an ambulatory CR program (all age groups)\n* Written informed consent\n\nExclusion Criteria:\n\n* Inability to follow an ambulatory CR program more than 3 weeks\n* Not willing to give informed consent\n* Inability to understand the informed consent due to language comprehension\n* Lack of discernment",{"count":656,"type":22},4000,"15 Years","The SwissPR study is to continuously monitor patient characteristics and short- and long-term benchmark quality measures and outcomes of patients participating in a 12-week ambulatory CR program.",[30],[661,662,663,664,665,666,667],"Coronary artery disease (CAD)","Cardiac rehabilitation (CR)","Acute coronary syndrome (ACS)","Chronic coronary syndrome (CCS)","Prevention benchmark performance measures (BPM)","KARAMBA","Swiss Prevention and Rehabilitation Registry (SwissPR)","2025-07-21",{"date":618,"type":45},{"date":671,"type":45},"2019-12-20",{"date":673,"type":22},"2035-12",{"name":675,"class":52},"University Hospital, Basel, Switzerland",{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":683,"enrollmentInfo":684,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":686,"conditions":687,"keywords":692,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":698,"lastUpdatePostDateStruct":699,"startDateStruct":701,"completionDateStruct":703,"leadSponsor":705,"locationsCount":53},"100589343","epigenetics-and-ncd-prevention-in-kazakhstan-personalized-approaches-and-biological-age-prediction-100589343","NCT06953180","Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction","Epigenetics and Prevention of Non-communicable Diseases in Kazakhstan: a Personalized Approach and Biological Age Prediction","Inclusion Criteria:\n\n* Adults aged 18 to 69 years.\n* Residents of 17 regions of Kazakhstan.\n* Willingness to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Age less than 18 years old or over 69 years old.\n* Failure to provide informed consent or incomplete participation in data collection procedures.","69 Years",{"count":685,"type":22},6720,"This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and developing health improvement recommendations.",[30,688,689,690,691],"Type 2 Diabetes","Chronic Respiratory Diseases","Obesity (Disorder)","Chronic Kidney Diseases",[693,694,695,696,697],"DNA methylation","precision medicine","preventive medicine","artificial intelligence","biomedical modeling","2025-07-08",{"date":700,"type":45},"2025-07-11",{"date":702,"type":45},"2025-03-03",{"date":704,"type":22},"2026-12-31",{"name":706,"class":52},"Asfendiyarov Kazakh National Medical University",{"id":708,"slug":709,"hasResults":12,"nctId":710,"briefTitle":711,"officialTitle":711,"acronym":4,"eligibilityCriteria":712,"healthyVolunteers":117,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":713,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":714,"conditions":715,"keywords":716,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":720,"lastUpdatePostDateStruct":721,"startDateStruct":723,"completionDateStruct":725,"leadSponsor":727,"locationsCount":53},"100597788","clinical-research-on-68ga-fapi-petcmr-in-cardiovascular-diseases-100597788","NCT07063043","Clinical Research on 68Ga-FAPI PET\u002FCMR in Cardiovascular Diseases","Inclusion Criteria:\n\n* Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings.\n* Age requirement: \\>18 years.\n* Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period.\n* Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures.\n\nExclusion Criteria:\n\n* History of malignancy\n* Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions\n* Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses\n* Claustrophobia\n* Pregnancy or lactation\n* Known hypersensitivity to gadolinium-based contrast agents\n* Renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² by CKD-EPI equation)",{"count":167,"type":22},"FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET\u002FCMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.",[30],[717,718,719],"Cardiovascular diseases","FAPI","PET\u002FMR","2025-07-03",{"date":722,"type":45},"2025-07-14",{"date":724,"type":45},"2024-12-01",{"date":726,"type":22},"2028-12-31",{"name":728,"class":52},"Shanghai East Hospital"]